% | $
Quotes you view appear here for quick access.

Ariad Pharmaceuticals Inc. Message Board

  • Aurileano Aurileano Jul 13, 1999 11:33 PM Flag

    July 14 ,1999.


    Richard Harmon, PeterSuzman,,
    Miljenko Zuanic, David Kincade, and .... Pirkkal,

    12 months hence...bliss=not. A bottle of Napa's best
    + entrees to ARGENT + FAS takes the day. Ariad will
    be at $8 by labor day.

    Ependymal cells are
    news. If you're well'll know why. Miljenko?
    Peter? Richard?

    Genomics are hot and Hazeltine
    bogarts the kliegs while Ariad, is patient....with cause.
    Berger willing to fund the lab by whatever means
    necessary to achieve stated goals

    Rod Searling, your day be here. Ignorance
    pervasive and persuasive.

    Odds to no acknowledgement
    of this post. Miljenko...Richard can't handle the
    'wild west' eh? Marquez could.

    SortNewest  |  Oldest  |  Most Replied Expand all replies

    • High Noon For Gene Therapy The article focuses on
      hemophilia, but a good read...and anything with Wilsonin
      there catches my eye."We are
      now in the era of the adeno-associated virus (AAV).
      This tiny virus, which can only replicate in the
      presence of adenovirus (hence the name), seems ideal. It
      infects both dividing and non-dividing cells; it causes
      far less of an immune response than the adenovirus;
      and it apparently integrates its DNA package into the
      genome of host cells, leading to long-lasting
      expression. And AAV does not cause any disease, as far as
      anyone knows, so it appears safer than other viral
      vectors."At had visions of selling a nice chunk of Magain
      todayand grabbing another "third" of Ariad...but it was
      not tobe. And what a shame...toward the end of the
      sessionthere my shares were...10k of them dumped at 1
      1/8th.Yup, I actually hold 20k shares of this puppy, nearly
      aquarter of my stock holdings...I don't call the
      portfolio"Mike's Microcap Madness" for nothing.Anyway, enough chit the Signals article, itwill remind you of the
      incredible challenges of gene therapy...but then go back and
      read the pnas paperto cheer you up. That is what I
      did. No, I wont be grabbing any additional shares, but
      I still have high hopes for Ariad. High hopes at
      high noon...Mad Dogs and Englishmen.

    • You can find a recent report from Small Caps on Line at:


    • This board seems to have serious posters. I am
      new to it. Because of BBBiotech's position I am
      considering investing in Ariad. But it looks to be running
      out of money, to put it bluntly. What does it have or
      what will it have that might attract more money to it?
      Is it, in short, headed for bankruptcy or for a new
      infusion of funds? Is it worth a gamble?

    • Aurileano...thanks fr your reply....i should have read the article more carefully....i completely misunderstood it....


    • Aurileano. Hands down kind sir, your last two
      posts have placed you in the pantheon of biotech
      contributors. There's no one here, or on Silicon Investor, who
      matches your intelligence or your ability to express the
      thrust of complex science so that all may understand.
      The fact that a well respected poster on SI gave you,
      a Yahoo participant, a direct link, without
      comment, is a highly uncommon, and noteworthy event

      Congratulations on your skills, knowledge, and

      Now, if you please, answer a direct, though, perhaps
      not simple, question: what is your opinion of Dr.
      Berger? I'm well aware that biofreak2 and others are
      dogmatically constrained. This dogma so often involves post
      hoc rationalizations (the stock price has dropped
      substantially therefore, the CEO must be incompetent) that any
      talent in the CEO is masked.

      Thus, if you or
      anyone else replies, I expect one of your rational and
      concise answers ...rather than the rumor-based nonsense
      we see here............and especially on SI.

    • Your concern - and everyone else's for that
      matter - should be significant indeed....if what you
      stated were true. However, the paper did not study the
      host's T cells but rather the role of the host's antigen
      presenting cells (APCs). APCs present antigen in the proper
      context to T cells in order to initiate an immune
      response. The group eliminated APCs in the host and thereby
      eliminated the ability of the donor T cells from responding.
      This is a unique angle to address GvHD: most
      approaches try to eliminate the donor T cells prior to
      delivery of the BMT. Their data shows that such an
      approach can work to greatly reduce the risk of

      But eliminating (or, more accurately, blocking) a
      (human) patient's APCs is a daunting and risky
      task....and it has never been done before. The group has
      shown that anti-APC antibodies will bind correctly to
      mouse lymph nodes. But they haven't yet shown this
      approach will block the APC function on these cells. So
      the baseline conditions to establish a permissive
      environment (void of APCs) in vivo has not been worked out in
      mice...and thus is still a distant concept for human
      application. There's also the problem that if the donor T
      cells never 'see' host APC, then how will the help
      fight recurrence of the cancer for which they were to
      play an important role?

      This work does not
      effect the underlying scientific concept which Ariad is
      basing its treatment approach. Donor T cells are still
      the 'culprit' in GvHD...and it was always known that
      host APC were providing the substrate to activate

      The ARGENT system for GvHD has its own
      problems. But as far as I know (important caveat), it's the
      only one where the residual host APC remains intact
      and the full complement donor T cells is provided.
      Thus the patient, at least at the outset of treatment,
      is receiving the most effective form BMT possible

    • PERhaps this abstract gives some indication. The research of Prof. Bordignon is in my knowledge closely related to Aria's


    • It is my understanding that Ariad's approach to
      GVHD is the elimination of DONOR T Cells after
      transplantaion. The idea is that these cells are the culprit in
      GVHD. The elimination of these cells would therefore
      stop the progression of GVHD dead in its

      A paper in the latest issue of SCIENCE (shlomchik
      et al) suggests that the real culprit in GVHD is not
      the DONOR T Cells, but rather the HOST T Cells.
      Essentially their seminal finding is that blocking antigen
      presentaion in Host cells is very protective against

      My concern is that this may have negative
      implications for Ariad's efforts in this area. In other words,
      if it is the HOST cells that are responsible for the
      disease, then would elimination of DONOR cells after
      transplantation be an effective treatment.....

      I would
      appreciate comments from people who may be a bit more
      up-to-date on Ariad's animal work in this regard. Just how
      effective has Ariad's approach to GVHD been in similar
      animal models of the disease. I wasn't able to find much
      in a quick PubMed search. An interesting experiment
      would be to essentially repeat the work described in
      this paper using donor T cells which have been
      engineered with Ariad's technology.


    • Swiss Biotech Fund BB Biotech is keeping its ARIAD position at 2.273.000 shares.


    • View More Messages
10.25+0.05(+0.49%)Aug 26 4:00 PMEDT